Published on 29/11/2025

Training for ATMP PPQ/CPV Teams

The biopharmaceutical industry faces increasingly complex challenges when developing advanced therapy medicinal products (ATMPs). As regulatory expectations evolve, the emphasis on robust process validation, specifically regarding performance qualification (PPQ) and continued process verification (CPV), has become paramount. This article serves as a comprehensive guide for professionals involved in ATMP PPQ and CPV, focusing on critical areas such as viral clearance validation, closed and single-use systems, and aseptic controls per Annex 1.

Understanding the Fundamentals of PPQ and CPV for ATMPs

Process validation is a crucial aspect of the quality assurance framework within the pharmaceutical industry as defined by the FDA. As it pertains specifically to ATMPs, it ensures that manufacturing processes consistently produce products that meet predetermined quality attributes and comply with regulatory requirements.

PPQ typically occurs after the installation of manufacturing equipment and before commercial production begins. It is intended to verify that the process is capable of reproducibly manufacturing products within specified quality attributes. CPV, on the other hand, involves ongoing monitoring of processes throughout their lifecycle to maintain product quality and performance post-approval.

Key areas of focus should include:

• Potency and Identity Critical Quality Attributes (CQAs): Understanding and defining the potency and identity of your ATMP is fundamental.
• Chain of Identity (COI): Ensuring traceability of product from source to final output is essential for regulatory compliance.
• Chain of Control (COC): Establishing procedures and controls that guard against contamination and ensure integrity throughout manufacturing.

Regulatory standards such as ICH Q5A(R2) emphasize the need for a robust validation strategy tailored to the specific risks associated with ATMPs.

Preparing for Viral Clearance Validation

The validation of viral clearance is a mandatory requirement for ATMPs, ensuring that final products are free from viral contamination. The validation process involves comprehensive studies that demonstrate the effectiveness of the manufacturing process in removing or inactivating viruses.

Steps for effective viral clearance validation include:

• Identification of Potential Viral Contaminants: Identify potential sources of viral contamination relevant to the biological process used.
• Selection of Viral Clearance Strategies: Choose appropriate methodologies—such as membrane filtration, heat inactivation, or solvent/detergent treatment—based on Scientific rationale.
• Design of Spiking Studies: Conduct spiking studies using a wide range of viruses to validate that the chosen strategies effectively reduce viral load to acceptable levels.

When executing spiking studies, it’s essential to select relevant viruses, perform replication under controlled conditions, and analyze the recovery rates effectively. Proper documentation of the methodology and results is vital for demonstrating compliance during regulatory submissions.

Implementing Closed Systems and Single-Use Systems

Closed systems and single-use systems (SUS) have gained prominence in ATMP production due to their advantages in minimizing contamination risks and reducing cleaning validation requirements. However, these systems also need careful validation to ensure their efficacy and reliability.

The implementation process can be detailed as follows:

• System Design Evaluation: Assess the design of closed and single-use systems to ensure that they align with regulatory expectations. They should be designed to prevent contamination and maintain a sterile environment throughout all production phases.
• Validation of Sterilization Procedures: Ensure that all materials and components used in the closed and single-use systems undergo rigorous sterilization validation to demonstrate that they are free of microbial contamination.
• Integration with Manufacturing Processes: Confirm that these systems are fully integrated into your established manufacturing processes without interrupting workflow or compromising product quality.

Additional attention should be paid to training teams on the correct operation and monitoring of these systems to maximize efficacy and minimize risks.

Aseptic Controls in Compliance with Annex 1 Guidelines

Annex 1 of the EU good manufacturing practices (cGMP) sets stringent guidelines for sterile production, particularly applicable to ATMPs. A thorough understanding of these controls is vital for any professional in this field.

The following steps should be addressed to align with aseptic control requirements:

• Environmental Monitoring: Regularly assess and monitor the production environment, including air quality, surface contamination, and personnel hygiene. Establish baseline contamination levels to determine acceptable limits.
• Personnel Training: Implement comprehensive training programs that cover aseptic techniques, gowning procedures, and contamination prevention strategies to create a culture of quality and compliance.
• Equipment Qualification: All systems utilized in the production environment should undergo qualification to ensure they operate within defined parameters and do not pose a contamination risk.

Engaging quality assurance teams early in this process can ensure that all aspects of aseptic production are appropriately validated according to regulatory obligations, facilitating smoother inspections by regulatory authorities.

PPQ and CPV Tailoring for ATMPs

As ATMPs vary significantly from traditional pharmaceuticals in terms of complexity and manufacturing processes, tailoring PPQ and CPV strategies is critical for regulatory compliance and effective quality assurance.

The following considerations should guide the tailoring process:

• Risk Assessment: Conduct thorough risk assessments to identify potential failure modes and their impact on product quality, which can inform targeted validation efforts.
• Stage-Specific Protocols: Develop specific protocols for PPQ and CPV phases, accounting for the unique characteristics of the ATMP and its production environment.
• Feedback Mechanisms: Implement feedback systems that allow for continuous learning and adaptation based on data collected during CPV operations.

This targeted approach increases the likelihood of compliance with expectations from authorities such as the EMA, FDA, and MHRA while ensuring the integrity and safety of the final product.

Conclusion: The Importance of Training for ATMP PPQ/CPV Teams

The evolving landscape of ATMP development necessitates comprehensive training for PPQ/CPV teams to navigate the complexities introduced by modern manufacturing practices. Effectively validating processes and ensuring compliance with regulatory standards helps guarantee the safety, efficacy, and quality of ATMPs, thereby safeguarding patient health.

Investing in rigorous training and aligning with best practices in viral clearance validation, aseptic controls, and tailored PPQ/CPV strategies ensures that pharma professionals are equipped to address these challenges head-on.